Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disul?de and sorafenib in liver cancer cells

Hepatocellular carcinoma(HCC)is a major health problem worldwide with high incidence and mortality rate[1,2].Proper treatments for HCC mainly include surgical resection,transcatheter arterial chemoembolization(TACE),radiofrequency ablation(RFA),and liver transplantation.However,many patients who are diagnosed with advanced HCC are not eligible for surgery,even the TACE and RFA does not necessarily have a good therapeutic effect.Until now,sorafenib is currently the first-line antitumor drug for the treatment of patients with advanced HCC.